Haider Mahdi

Dr. Haider Mahdi


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 September 2021 in JCO Precision Oncology
Verified
Journal Article
Open access
HMHaider Mahdi
Haider Mahdi
NHNavid Hafez
Navid Hafez
DDDeborah Doroshow
Deborah Doroshow
DSDavendra Sohal
Davendra Sohal
VKVickie Keedy
Vickie Keedy
JEJoseph Paul Eder
Joseph Paul Eder
PURPOSE: Poly (ADP-ribose) polymerase (PARP) inhibitors have emerged as promising therapy in cancers with homologous recombination repair deficiency. However, efficacy is limited by both intrinsic and acquired resistance. The Olaparib Combinations basket trial explored olaparib alone and in combination with other homologous recombination–directed targeted therapies. Here, we report the results of the arm in which olaparib was combined with the orally bioavailable ataxia telangiectasia and RAD3-related inhibitor ceralasertib in patients with relapsed or refractory cancers harboring DNA damage response and repair alterations, including patients with BRCA-mutated PARP inhibitor–resistant high-grade serous ovarian cancer (HGSOC). PATIENTS AND METHODS: Germline and somatic mutations had to be deleterious by COSMIC or ClinVar for eligibility. Olaparib was administered at 300 mg twice daily and ceralasertib at 160 mg daily on days 1-7 in 28-day cycles until progression or unacceptable toxicities. Primary end points were confirmed complete response (CR) or partial response (PR) rates and clinical benefit rate (CBR; CR + PR + stable disease [SD] at 16 weeks). RESULTS: Twenty-five patients were enrolled, with median four prior therapies. Five patients required dose reductions for myelosuppression. Overall response rate was 8.3% and CBR was 62.5% among the entire cohort. Two of five patients with tumor harboring ATM mutation achieved CR or SD ongoing at 24+ months, respectively (CBR 40%). Of seven patients with PARP inhibitor–resistant HGSOC, one achieved PR (–90%) and five had SD ranging 16-72 weeks (CBR 86%). CONCLUSION: Olaparib with ceralasertib demonstrated preliminary activity in ATM-mutated tumors and in PARP inhibitor–resistant BRCA1/2–mutated HGSOC. These data warrant additional studies to further confirm activity in these settings.

17 December 2021 in npj Precision Oncology
Verified
Journal Article
Open access
PDF file
YNYing Ni
Ying Ni
ASAhmed Soliman
Ahmed Soliman
AJAmy Joehlin-Price
Amy Joehlin-Price
PRPeter G. Rose
Peter G. Rose
AVAnda Vlad
Anda Vlad
HMHaider Mahdi
Haider Mahdi
Various immune signatures predictive of resistance to immune checkpoint inhibitors (ICI) have been described in multiple solid cancers, but still under-investigated in gynecological (GYN) cancer. For 49 GYN cancer patients included in our study, without transcriptome signature, immune-related toxicity was the only clinical predictor of ICI treatment response (p = 0.008). The objective clinical response was the only predictor of progression-free survival (ICI-PFS, p = 0.0008) and overall survival (ICI-OS, p = 0.01). Commonly used ICI marker PD-L1 expression negatively correlated with progression-free survival (ICI-PFS) (p = 0.0019). We performed transcriptome and signaling pathway enrichment analyses based on ICI treatment responses and the survival outcome, and further estimated immune cell abundance using 547 gene markers. Our data revealed that TGF-β regulated signaling pathway was noted to play an important role in immunotherapy failure. Using our 6-genes TGF-β score, we observed longer ICI-PFS associated with lower TGF-β score (8.1 vs. 2.8 months, p = 0.046), which was especially more prominent in ovarian cancer (ICI-PFS 16.6 vs. 2.65 months, p = 0.0012). Further, abundant immunosuppressive cells like T-regulatory cells, eosinophils, and M2 macrophages were associated with shorter ICI-OS and correlated positively with CD274 and CTLA4 expressions. This study provides insight on the potential role of TGF-β in mediating immunotherapy resistance and cross-talking to immunosuppressive environment in GYN cancer. The TGF-β score, if validated in a larger cohort, can identify patients who likely to fail ICI and benefit from targeting this pathway to enhance the response to ICI.

31 December 2014 in Archives of Gynecology and Obstetrics
Verified
Journal Article
Closed access
PDF file
HMHaider Mahdi
Haider Mahdi
AMAdnan R. Munkarah
Adnan R. Munkarah
RARouba Ali-Fehmi
Rouba Ali-Fehmi
JWJessica Woessner
Jessica Woessner
SSShetal N. Shah
Shetal N. Shah
MMMehdi Moslemi-Kebria
Mehdi Moslemi-Kebria

19 July 2023 in npj Precision Oncology
Verified
Journal Article
Open access
PDF file
HAHussein Al-Sudani
Hussein Al-Sudani
YNYing Ni
Ying Ni
PJPhilip Jones
Philip Jones
HKHuseyin Karakilic
Huseyin Karakilic
LCLei Cui
Lei Cui
HMHaider Mahdi
Haider Mahdi
The objective was to correlate CD47 gene expression with resistance to immune checkpoint inhibitors (ICI) in tumor tissue of gynecological cancer (GC). Further, we sought to assess the efficacy of targeting CD47 pathway alone and in combination in pre-clinical ovarian cancer (OC) models. We performed transcriptomic analyses in GC treated with ICI. Signaling pathway enrichment analysis was performed using Ingenuity Pathway Analysis. Immune cell abundance was estimated. CD47 expression was correlated with other pathways, objective response, and progression-free survival (PFS). Anti-tumor efficacy of anti-CD47 therapy alone and in combination was investigated both in-vitro and in-vivo using cell-line derived xenograft (CDX) and patient-derived xenograft (PDX) models. High CD47 expression associated with lower response to ICI and trended toward lower PFS in GC patients. Higher CD47 associated negatively with PDL1 and CTLA4 expression, as well as cytotoxic T-cells and dendritic cells but positively with TGF-β, BRD4 and CXCR4/CXCL12 expression. Anti-CD47 significantly enhanced macrophage-mediated phagocytosis of OC cells in-vitro and exhibited potent anti-tumor activity in-vivo in OC CDX and PDX models. In-vitro treatment with PARPi increased CD47 expression. Anti-CD47 led to significantly enhanced in-vitro phagocytosis, enhanced STING pathway and synergized in-vivo when combined with PARP inhibitors in BRCA-deficient OC models. This study provides insight on the potential role of CD47 in mediating immunotherapy resistance and its association with higher TGF-β, BRD4 and CXCR4/CXCL12 expression. Anti-CD47 showed potent anti-tumor activity and synergized with PARPi in OC models. These data support clinical development of anti-CD47 therapy with PARPi in OC.

1 February 2014 in Gynecologic Oncology
Verified
Journal Article
Closed access
HMHaider Mahdi
Haider Mahdi
CSCary Jo Schlick
Cary Jo Schlick
LKLi-Lian Kowk
Li-Lian Kowk
MMMehdi Moslemi-Kebria
Mehdi Moslemi-Kebria
CMChad Michener
Chad Michener

1 November 2016 in Journal of Minimally Invasive Gynecology
Verified
Journal Article
Closed access
HMHaider Mahdi
Haider Mahdi
QAQataralnada Aljebori
Qataralnada Aljebori
DLDavid Lockart
David Lockart
LMLaura Moulton
Laura Moulton